Shares in US pharma giant Merck & Co (NYSE: MRK) were down by more than 3% at lunchtime Thursday after the company presented its latest financial results.
In fact, it was the firm’s pessimistic outlook for 2023 that likely sent shares downwards, rather than the financial performance figures for the fourth quarter of 2022 and the year as a whole.
"An exceptional year for Merck"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze